Vineet Laboratories Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Latest quarter profit grew 168.9% YoY, showing strong momentum
- Working capital cycle has improved - days down from 30 to -34
CONS
- Company is loss-making at the operating / net level
- Company has a high debt-to-equity of 2.73x
- Company has a low return on equity of -25.0% over last 3 years
- Promoter holding has decreased over last 2 years: -31.5pp
- Company has a low return on capital employed of -3.1%
- Interest coverage is weak at -4.2x - earnings barely cover interest
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | 1842.00 | 36.54 | 441957.50 | 0.87 | 2901.23 | 26.53 | 15299.88 | 10.98 | 19.11 | 28.81 |
| DIVISLAB | 9326.00 | 84.64 | 247576.00 | 0.32 | 902.00 | 65.50 | 3080.00 | 27.80 | 21.51 | 40.75 |
| TORNTPHARM | 4975.00 | 86.76 | 189233.01 | 0.76 | 566.00 | 3.28 | 4921.00 | 57.32 | 19.27 | 33.81 |
| ZYDUSLIFE | 1119.50 | 24.74 | 111670.55 | 0.09 | 990.20 | -34.90 | 8017.00 | 23.97 | 21.39 | 24.54 |
| CIPLA | 1365.00 | 32.72 | 110272.68 | 0.95 | 785.55 | -39.18 | 7119.28 | 4.13 | 16.00 | 16.73 |
| LAURUSLABS | 1970.35 | 97.37 | 106460.42 | 0.10 | 362.07 | 123.94 | 2026.31 | 29.10 | 18.20 | 31.50 |
| DRREDDY | 1161.00 | 30.07 | 96906.38 | 0.69 | 435.60 | -69.10 | 8099.80 | -5.21 | 13.75 | 10.63 |
| AUROPHARMA | 1675.45 | 25.97 | 96401.69 | 0.24 | 1032.03 | 25.22 | 9150.35 | 17.44 | 12.76 | 20.54 |
| LUPIN | 2096.00 | 17.34 | 95842.92 | 0.86 | 1416.98 | 16.01 | 8276.89 | 34.28 | 28.86 | 29.59 |
| MANKIND | 2277.00 | 46.04 | 94050.37 | 0.04 | 574.09 | 29.12 | 4030.59 | 12.89 | 13.24 | 26.30 |
| GLENMARK | 2416.90 | 37.94 | 68210.88 | 0.10 | 482.83 | 927.88 | 4018.48 | 31.35 | 20.35 | 20.03 |
| VINEETLAB | 36.96 | 63.89 | 70.99 | 0.00 | 7.25 | 168.85 | 188.91 | 1241.69 | -25.12 | 13.20 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57 | 38 | 43 | 33 | 37 | 24 | 19 | 18 | 14 | 7 | 17 | 16 | 189 | |
| 51 | 37 | 39 | 33 | 34 | 25 | 19 | 22 | 25 | 7 | 14 | 13 | 179 | |
| Operating Profit | 6 | 0 | 4 | -1 | 3 | -1 | -0 | -4 | -11 | 0 | 3 | 2 | 10 |
| OPM % | 10.14% | 0.69% | 9.59% | -1.96% | 9.23% | -3.35% | -1.58% | -22.87% | -78.41% | 4.30% | 18.20% | 15.91% | 5.10% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 10 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 |
| Profit before Tax | 5 | -1 | 3 | -2 | 1 | -2 | -2 | -6 | -11 | -1 | 0 | 1 | 10 |
| Tax % | 26.80% | 2.34% | 5.12% | 11.59% | -34.27% | 1.84% | -7.02% | -0.53% | 6.24% | 4.44% | -8.11% | -3.66% | 27.06% |
| Net Profit | 4 | -1 | 2 | -2 | 2 | -2 | -2 | -6 | -11 | -1 | 0 | 1 | 7 |
| 3.85 | -1.36 | 2.62 | -2.24 | 2.09 | -2.31 | -1.98 | -6.19 | -11.42 | -0.94 | 0.43 | 0.92 | 0.43 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 243 | 191 | 212 | 151 | 75 | 229 | |
| 0 | 0 | 0 | 235 | 178 | 205 | 143 | 91 | 214 | |
| Operating Profit | 0 | 0 | -0 | 8 | 13 | 8 | 7 | -16 | 16 |
| OPM % | — | — | — | 3.35% | 6.88% | 3.61% | 4.78% | -21.71% | 6.81% |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | |
| Interest | 0 | 0 | 0 | 3 | 2 | 3 | 5 | 4 | 14 |
| Depreciation | 0 | 0 | 0 | 2 | 2 | 2 | 3 | 3 | 7 |
| Profit before Tax | 0 | 0 | -0 | 4 | 9 | 2 | 0 | -21 | 10 |
| Tax % | — | — | -0.00% | 56.13% | 28.96% | 38.30% | -182.64% | 2.81% | 25.32% |
| Net Profit | 0 | 0 | -0 | 2 | 7 | 1 | 1 | -20 | 8 |
| EPS | 0.00 | 0.00 | 0.00 | 2.18 | 7.20 | 1.36 | 1.11 | -21.90 | — |
| Dividend Payout % | — | — | 0.00% | 0.00% | 13.89% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- -27%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- -11%
- 3 Years:
- -4%
- 1 Year:
- 29%
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- -8%
- 3 Years:
- -25%
- Last Year:
- -82%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 0 | 9 | 9 | 9 | 9 | 9 |
| 0 | 0 | -0 | 17 | 24 | 24 | 26 | 5 | |
| 0 | 0 | 0 | 13 | 27 | 30 | 43 | 39 | |
| Trade Payables | 0 | 0 | 0 | 56 | 60 | 35 | 32 | 34 |
| 0 | 0 | 0 | 13 | 13 | 17 | 7 | 7 | |
| Total Liabilities | 0 | 0 | 0 | 109 | 133 | 116 | 117 | 95 |
| 0 | 0 | 0 | 20 | 21 | 27 | 27 | 25 | |
| 0 | 0 | 0 | 40 | 44 | 46 | 49 | 50 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 32 | 13 | |
| Cash & Bank | 0 | 0 | 0 | 2 | 18 | 1 | 0 | 1 |
| 0 | 0 | 0 | 47 | 50 | 42 | 8 | 5 | |
| Total Assets | 0 | 0 | 0 | 109 | 133 | 116 | 117 | 95 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 0 | 0 | -0 | 27 | 11 | -7 | -7 | 11 | |
| Cash from Investing | 0 | 0 | 0 | -8 | -4 | -7 | -2 | -3 |
| Cash from Financing | 0 | 0 | 0 | 19 | 12 | 0 | 8 | -8 |
| 0 | 0 | -0 | 38 | 16 | -16 | -0 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-08 - The Exchange has sought clarification from Vineet Laboratories Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Financial Results not submitted The response of the Company is awaited.
2026-08-29 - Vineet Laboratories Limited has informed the Exchange about General Updates
2026-08-25 - Vineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
2026-08-25 - Vineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.The Board of Directors of the company in its meeting held today i.e., on August 25, 2026 has:Approved the Audited Standalone Financial Results of the Company for the fourth quarter and the financial year ended on 31 March, 2026 and the Audited Standalone Financial Statement for the financial year ended on 31* March 2026 along with Audit Report.
2026-08-14 - Please find the attached Monitoring Agency Report issued by CRISIL rating Limited for quarter ended June 30, 2026
2026-07-30 - Vineet Laboratories Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__
2026-07-30 - Vineet Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-07-21 - Vineet Laboratories Limited has informed the Exchange regarding Cessation of Mr. Gaddam Venkata Ramana (DIN: 00031873) as Managing Director of the company w.e.f. July 21, 2026.
2026-07-21 - Vineet Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company.
News
Recent coverage and analyst commentary for VINEETLAB
Loading news…
AI Stock Analyst
Vineet Laboratories Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account